Topic: Rheumatoid Arthritis

2017 Interventions of Interest: TNF Inhibitors Adalimumab (Humira®, Abbvie) Certolizumab pegol (Cimzia®, UCB) Etanercept (Enbrel®, Amgen) Golimumab (Simponi®, Janssen) Infliximab (Remicade®, Janssen) CD20- Directed Cytolytic Antibody Rituximab (Rituxan®, Genentech) T Cell Inhibitor Abatacept (Orencia®, BMS) IL-6 Inhibitors Sarilumab (Kevzara®, Sanofi and Regeneron Pharmaceuticals) Tocilizumab (Actemra®, Genentech) JAK- Inhibitors Tofacitinib (Xeljanz®, Pfizer) Baricitinib (Olumiant®, Eli Lilly […]

Interventions of Interest: JAK- Inhibitors Baricitinib (Olumiant®, Eli Lilly and Co.) Tofacitinib (Xeljanz®, Pfizer) Upadacitinib (Rinvoq™, AbbVie) adalimumab (Humira®, AbbVie) Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages […]